$1.3 Billion is the total value of FRAZIER MANAGEMENT LLC's 35 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 45.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $296,569,000 | -4.0% | 10,542,790 | 0.0% | 22.84% | -17.6% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $193,587,000 | -9.4% | 5,827,415 | 0.0% | 14.91% | -22.3% | |
| PASG | PASSAGE BIO INC | $128,086,000 | +95.0% | 5,009,219 | 0.0% | 9.86% | +67.3% | |
| TARS | New | TARSUS PHARMACEUTICALS INC | $79,236,000 | – | 1,917,157 | +100.0% | 6.10% | – |
| MIRM | MIRUM PHARMACEUTICALS INC | $62,278,000 | -9.4% | 3,566,912 | 0.0% | 4.80% | -22.3% | |
| PCVX | VAXCYTE INC | $61,365,000 | -46.2% | 2,309,554 | 0.0% | 4.73% | -53.8% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $60,923,000 | +40.9% | 1,312,999 | 0.0% | 4.69% | +20.9% | |
| KRYS | KRYSTAL BIOTECH INC | $53,700,000 | +39.4% | 895,000 | 0.0% | 4.14% | +19.5% | |
| Buy | TRILLIUM THERAPEUTICS INC | $44,879,000 | +13.5% | 3,053,107 | +9.5% | 3.46% | -2.7% | |
| TBIO | TRANSLATE BIO INC | $40,229,000 | +35.4% | 2,182,789 | 0.0% | 3.10% | +16.2% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $32,400,000 | +43.3% | 2,571,450 | 0.0% | 2.50% | +23.0% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $31,248,000 | +60.4% | 1,405,045 | +6.4% | 2.41% | +37.6% |
| STRO | New | SUTRO BIOPHARMA INC | $21,741,000 | – | 1,001,421 | +100.0% | 1.67% | – |
| ANAB | Sell | ANAPTYSBIO INC | $19,344,000 | -43.4% | 899,700 | -61.2% | 1.49% | -51.4% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $18,902,000 | -3.8% | 943,666 | 0.0% | 1.46% | -17.5% | |
| ISEE | Buy | IVERIC BIO INC | $17,237,000 | +29.3% | 2,494,500 | +5.5% | 1.33% | +10.9% |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $15,577,000 | +5.2% | 1,437,028 | 0.0% | 1.20% | -9.7% | |
| FLACU | New | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $15,580,000 | – | 1,501,000 | +100.0% | 1.20% | – |
| RGNX | Buy | REGENXBIO INC | $15,511,000 | +223.6% | 341,954 | +96.3% | 1.19% | +177.7% |
| APTX | APTINYX INC | $11,038,000 | +2.4% | 3,190,079 | 0.0% | 0.85% | -12.2% | |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $10,227,000 | +177.2% | 568,500 | +118.7% | 0.79% | +138.1% |
| FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $10,043,000 | +17.0% | 550,000 | 0.0% | 0.77% | +0.3% | |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $9,213,000 | -23.7% | 168,000 | -68.2% | 0.71% | -34.6% |
| GRTS | GRITSTONE ONCOLOGY INC | $8,123,000 | +48.7% | 2,061,758 | 0.0% | 0.63% | +27.5% | |
| EPZM | New | EPIZYME INC | $7,943,000 | – | 731,436 | +100.0% | 0.61% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $7,906,000 | – | 841,908 | +100.0% | 0.61% | – |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $7,449,000 | – | 153,500 | +100.0% | 0.57% | – |
| ALNA | ALLENA PHARMACEUTICALS INC | $4,263,000 | -13.5% | 3,330,373 | 0.0% | 0.33% | -26.0% | |
| BLU | BELLUS HEALTH INC NEW | $3,898,000 | +31.7% | 1,296,743 | 0.0% | 0.30% | +12.8% | |
| SRRA | SIERRA ONCOLOGY INC | $3,251,000 | +50.2% | 202,803 | 0.0% | 0.25% | +28.9% | |
| GRTX | New | GALERA THERAPEUTICS INC | $2,465,000 | – | 241,000 | +100.0% | 0.19% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $1,657,000 | – | 35,750 | +100.0% | 0.13% | – |
| ITRM | ITERUM THERAPEUTICS PLC | $1,521,000 | -5.8% | 1,538,316 | 0.0% | 0.12% | -19.3% | |
| New | NABRIVA THERAPEUTICS PLC | $1,030,000 | – | 425,650 | +100.0% | 0.08% | – | |
| NERV | Sell | MINERVA NEUROSCIENCES INC | $144,000 | -91.8% | 61,541 | -88.8% | 0.01% | -93.0% |
| ETTX | Exit | ENTASIS THERAPEUTICS HLDGS I | $0 | – | -199,953 | -100.0% | -0.04% | – |
| Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -105,144 | -100.0% | -0.06% | – | |
| VTVT | Exit | VTV THERAPEUTICS INCcl a | $0 | – | -1,062,000 | -100.0% | -0.17% | – |
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -4,256,526 | -100.0% | -0.20% | – | |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -1,312,258 | -100.0% | -0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.